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A yeast two-hybrid assay was employed to identify
androgen receptor (AR) protein partners in gonado-
tropin-releasing hormone neuronal cells. By using an
AR deletion construct (AR-(371–485)) as a bait, -cate-
nin was identified as an AR-interacting protein from a
gonadotropin-releasing hormone neuronal cell library.
Immunolocalization of co-transfected AR and FLAG--
catenin demonstrated that FLAG--catenin was pre-
dominantly cytoplasmic in the absence of androgen. In
the presence of 5-dihydrotestosterone, FLAG--catenin
completely co-localized to the nucleus with AR. This
effect was specific to AR because liganded progesterone,
glucocorticoid, or estrogen  receptors did not translo-
cate FLAG--catenin to the nucleus. Agonist-bound AR
was required because the AR antagonists casodex and
hydroxyflutamide failed to translocate -catenin. Time
course experiments demonstrated that co-translocation
occurred with similar kinetics. Nuclear co-localization
was independent of the glycogen synthase kinase-3,
p42/44 ERK mitogen-activated protein kinase, and phos-
phatidylinositol 3-kinase pathways because inhibitors
of these pathways had no effect. Transcription assays
demonstrated that liganded AR repressed -catenin/T
cell factor-responsive reporter gene activity. Con-
versely, co-expression of -catenin/T cell factor re-
pressed AR stimulation of AR-responsive reporter gene
activity. Our data suggest that liganded AR shuttles
-catenin to the nucleus and that nuclear interaction of
AR with -catenin may modulate transcriptional activ-
ity in androgen target tissues.
Androgen receptor (AR)1 is a member of the nuclear steroid
receptor superfamily and is vital for normal sexual develop-
ment in males (reviewed in Ref. 1). In androgen target cells, AR
is predominantly localized in the cytoplasmic fraction in the
absence of ligand and translocates to the nucleus in the pres-
ence of the endogenous androgens, testosterone and 5-dihy-
drotestosterone (5-DHT), where it activates transcription of
AR-responsive genes (2, 3). In addition to the genomic actions
of AR, nongenomic signaling mechanisms of androgens have
also been described in several cell systems. Through activation
of the Src/Shc/ERK signaling pathway, AR was shown to be
anti-apoptotic in osteoblasts, osteocytes, embryonic fibroblasts,
and HeLa cells (4). Activation of the ERK mitogen-activated
protein kinase pathway by AR has also been demonstrated in
prostate cancer cell lines (5). In bone, androgens have been
shown to increase intracellular calcium, diacylglycerol, and
inositol 1,4,5-trisphosphate formation (6).
The genomic actions of AR are dependent upon its nuclear
translocation where it then binds to androgen-response ele-
ments, some of which conform to the consensus sequence 5-
GG(A/T)ACANNNTGTTCT-3 (7), and stimulates the tran-
scription of target genes. Several androgen-response elements
are also recognized by the glucocorticoid receptor, and it is
believed that protein-protein interactions play a role to dis-
criminate AR- versus GR-mediated effects at these sites (8).
Other nuclear factors that modulate AR transcriptional activ-
ity include cAMP-response element-binding protein, AP-1, and
members of the POU family of homeodomain transcription
factors (8–11). Protein-protein interactions are also involved in
the role of AR as a transcriptional repressor independent of
DNA binding. Recently, the mechanism of AR repression of the
-glycoprotein hormone subunit gene in the T3-1 pituitary
gonadotrope cell line was found to be through interactions with
c-Jun and ATF-2 (12). Repression of the luteinizing hormone 
subunit gene involved protein-protein interactions between AR
and SF-1 (13). In a separate study, AR-mediated repression of
the luteinizing hormone  subunit gene was also found to occur
through protein-protein interactions with Sp1 and to a lesser
degree Egr-1 (14).
The yeast two-hybrid system has been used successfully to
identify protein partners of AR. Both co-activators and tran-
scriptional repressors have been found. For example, Chang
and colleagues (15–18) have identified the androgen receptor
co-activators ARA70, ARA55, ARA54, and ARA267 from yeast
two-hybrid screens of prostate cell libraries. Additionally,
TIP60, a co-activator of human immunodeficiency virus Tat
protein, and TRAM-1, a thyroid receptor co-activator, have
been isolated from yeast two-hybrid screens using AR as a bait
(19, 20). The androgen receptor-specific co-activator FHL2 was
also identified by a yeast two-hybrid screen (21). The amino-
terminal enhancer of split was identified as an AR repressor
using a yeast two-hybrid assay (22).
In this study, we performed a yeast two-hybrid screen using
a GT1-7 cell cDNA library to identify potential protein partners
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of AR in GT1-7 GnRH neuronal cells and found -catenin as an
AR-interacting protein. -Catenin was originally identified at
adherins junctions involved in the binding of cadherins with
the actin cytoskeleton (23) and therefore is important in the
regulation of cell adhesion. However, a role for -catenin in
development and signal transduction was proposed because of
sequence similarity with the Drosophila Armadillo protein that
is a component of the wingless signaling pathway (24). In the
absence of signaling mechanisms that stabilize cytoplasmic
-catenin, its levels in the cytoplasm are tightly regulated
because of phosphorylation by glycogen synthase kinase-3
(GSK-3) and subsequent proteosomal degradation (25, 26).
During development, Wnt signaling pathways inhibit -cate-
nin degradation and cause accumulation of cytoplasmic -cate-
nin (27). Subsequently, -catenin translocates to the nucleus
and forms a complex with the T cell factor/lymphoid enhancer
factor (TCF/Lef) family of transcription factors and stimulates
transcription of target genes. Because it lacks a nuclear local-
ization signal, the mechanisms for -catenin nuclear translo-
cation are not well understood. In our studies, we found that
agonist bound AR but not progesterone receptor (PR), glucocor-
ticoid receptor (GR), or estrogen receptor  (ER)-induced nu-
clear translocation of -catenin. Furthermore, liganded AR re-
pressed -catenin/TCF activation of -catenin/TCF-responsive
promoter activity. Conversely, -catenin/TCF expression re-
pressed AR-responsive promoter activity. Our results suggest
that interactions between AR and -catenin may modulate the
nuclear localization of -catenin and transcriptional activity in
AR-responsive target tissues.
EXPERIMENTAL PROCEDURES
Reagents—AR (PA1–111A), ER (PA1–308), GR (PA1–511A), and
polyclonal FLAG (PA1–984) antibodies were obtained from Affinity
Bioreagents (Golden, CO). Anti-PR (LS434) was a kind gift from Dean
Edwards (University of Colorado Health Sciences Center). Anti-Myc
(3F10), anti-GSK-3 (clone 7), and monoclonal anti--catenin (C19220)
were purchased from Transduction Laboratories (Lexington, KY). Poly-
clonal anti--catenin was from Santa Cruz Biotechnology (Santa Cruz,
CA). Phospho-GSK-3 antibody (9336) was purchased from Cell Signal-
ing Technology (Beverly, MA). Secondary anti-mouse and anti-rabbit
Texas Red or FITC-conjugated antibodies were obtained from Jackson
ImmunoResearch (West Grove, PA). The yeast Matchmaker 3 system
was purchased from CLONTECH (Palo Alto, CA). 5-DHT was pur-
chased from Steraloids (Wilton, NH). Casodex and hydroxyflutamide
were obtained from Zeneca Pharmaceuticals (Wilmington, DE) and
Schering Corp. (Kenilworth, NJ), respectively. All other reagents unless
otherwise noted were obtained from Sigma.
Cell Culture—Cell lines were grown in Dulbecco’s modified Eagle’s
medium supplemented with either 5 or 10% fetal calf serum, 100 units
of penicillin/ml, 100 g of streptomycin/ml, and 0.25 g/ml of ampho-
tericin B at 37 °C in humidified 5% CO2, 95% air. GT1-7 cells are
immortalized murine GnRH neuronal cells derived from an SV40 large
T antigen-targeted hypothalamic GnRH-producing tumor that displays
neuronal specific markers and produce GnRH (28). NLT cells are also
immortalized murine GnRH neuronal cells that produce GnRH but
were derived from an olfactory tumor, thus representing early migrat-
ing GnRH neuronal cells (29). COS-7 cells were obtained from the
Cancer Center Cell Culture Core facility, University of Colorado Health
Sciences Center.
Plasmids—pGBKT7-AR-(371–485) was generated by ligating PCR
products corresponding to nucleotides 1–1110 of rat AR (rAR) (amino
acids 1–370) to nucleotides 1458–2709 (amino acids 486–903) of rAR
into pGBKT7. Briefly, the forward 5-atgggtcgacatggaggtgcagtta-3 and
reverse 5-tttatgcatcggcccggacagagc-3 primers were used to generate
the 1–1110 fragment. The forward 5-ggcatgcattatcctggtggagttgtg-3
and reverse 5-tataggctgcagtcactgtgtgtggaa-3 primers were used to
generate the 1458–2709 fragment. Both fragments were ligated after
restriction enzyme digestion with NsiI. The ligation product was fur-
ther digested with PstI and then subcloned into pGBKT7 that had been
cut with SmaI and PstI. pCMV-rAR, pCMV-human AR (hAR), pCMV-
AR-(1–503), pCMV-AR-(1–660), pCMV-AR-R617K618,632,633M,
pCMV-AR-K720A, pCMV-AR-E897K and pCMV-AR-V716R were made
as described (2, 30–34). pCMV-myc-AR was generated by subcloning
hAR into the SfiI and NotI sites of pCMV-myc (CLONTECH). -Cate-
nin, TCF-4, and pGL3-OT plasmid constructs were kind gifts of Bert
Vogelstein and Ken Kinzler (The Johns Hopkins University, Baltimore,
MD). pGL3-OT contains a trimerized TCF optimal promoter sequence
upstream of the luciferase gene and is a modified version of the TOP-
FLASH vector (35). FLAG--catenin was a kind gift of E. R. Fearon
(University of Michigan, Ann Arbor, MI). MMTV-luciferase contains
sequences 1161 to 102 of the MMTV-long terminal repeat coupled to
a luciferase reporter gene (36). The human glucocorticoid receptor (GR)
construct RSHGR was a kind gift from Ron Evans, and human PR
(pSG5hPR) and ER were obtained from Pierre Chambon.
Yeast Two-hybrid Assay—Yeast two-hybrid analysis was performed
using the CLONTECH Matchmaker 3 system. A cDNA library gener-
ated from GT1-7 neuronal cell mRNA was subcloned into the Gal4
activation domain vector pGAD10. Rat AR-(371–485) was subcloned
into the bait plasmid pGBKT7 that contains the Gal4 DNA binding
domain to generate pGBKT7-AR-(371–485). Yeast AH109 cells were
sequentially transformed with the library vector and pGBKT7-AR-
(371–485). Approximately 4  106 independent clones were plated on
synthetic drop-out media (CLONTECH) without histidine, leucine, or
tryptophan in the presence of 30 mM 3-aminotriazole and 200 nM 5-
DHT. Positive clones were confirmed by replating and selecting clones
that grew in the presence, but not absence, of 5-DHT and by liquid
-galactosidase assays.
For the -galactosidase assays, pGBKT7-AR-(371–485) and poten-
tial positive interacting clones were transformed into Y187 cells. Cells
were grown to stationary phase in appropriate selection media and then
diluted 1:4 into 8 ml of YPD media. Cells were grown an additional 5 h
in the absence or presence of 10 nM 5-DHT. Cells were harvested and
lysed by three freeze/thaw cycles in buffer containing 100 mM sodium
phosphate, pH 7.0, 10 mM KCl, 1 mM MgSO4. To 0.1 ml of cell lysate was
added 0.7 ml of lysis buffer containing 40 mM -mercaptoethanol, fol-
lowed by 0.16 ml of lysis buffer containing 4 mg/ml of o-nitrophenyl
-D-galactopyranoside. Samples were incubated at 37 °C, and absorb-
ance values were measured at 420 nm.
Immunoprecipitation and Immunoblot Analysis—COS-7 cells were
co-transfected with pCMV-myc-AR and FLAG--catenin in the presence
of 10 nM 5-DHT. Cells were rinsed with cold PBS and lysed in buffer
containing 50 mM HEPES, pH 7.5; 0.5% Triton X-100; 5 mM EDTA; 50
mM NaCl; 10 mM sodium pyrophosphate; 50 mM NaF; 1 mM Na3VO4; 1
mM phenylmethylsulfonyl fluoride; 10 g/ml each aprotinin, leupeptin,
and pepstatin. For immunoprecipitation assays, 300 g of lysates were
incubated with 1 g anti-Myc antibody for 2 h at 4 °C. Immune com-
plexes were precipitated for 1 h using protein A  G (Oncogene Sci-
ences) and washed three times in lysis buffer prior to analysis by
SDS-PAGE and immunoblotting. Proteins were separated using 8%
SDS-PAGE, transferred to HyBond-P membranes (Amersham Bio-
sciences), and probed with either anti-Myc or anti-FLAG antibodies (1
g/ml each). For immunoblot analysis of cell extracts, 20–40 g of
whole cell lysates were separated using 8% SDS-PAGE, transferred to
HyBond-P, and incubated with either anti-Myc, anti-FLAG, or -cate-
nin antibodies. Immunoreactive proteins were visualized using ECL
(Amersham Biosciences) following the manufacturer’s directions.
Immunocytochemistry—NLT GnRH neuronal cells were cultured in
Dulbecco’s modified Eagle’s medium containing 5% charcoal-stripped
fetal bovine serum for 36–48 prior to transfection. For transfections,
15,000 NLT cells were plated on glass coverslips in 24-well plates and
allowed to attach overnight. Cells were transfected using 320 ng of
FLAG--catenin and 80 ng of steroid receptor constructs using Lipo-
fectAMINE plus (Invitrogen) and incubated for 16 h. For immunocyto-
chemistry, cells were rinsed with 1 ml PBS at RT and then fixed in 4%
paraformaldehyde/PBS for 30 min at RT. Cells were rinsed twice with
1 ml of PBS and then permeabilized with 0.5 ml of 5% bovine serum
albumin, 0.2% Triton X-100 in PBS for 90 min at RT. For double label
experiments, cells were incubated with either anti-AR (2 g/ml), an-
ti-PR (1:1000), or anti-GR (2 g/ml) and either monoclonal anti-FLAG
(M2 Sigma; 2 g/ml for AR and GR) or polyclonal anti-FLAG (2 g/ml
for PR) antibodies overnight at 4 °C in 3% bovine serum albumin in
PBS. Cells were then rinsed three times with PBS and incubated with
anti-rabbit or mouse secondary antibodies conjugated to either Texas
Red or FITC (1:1000) in 3% bovine serum albumin in PBS for 90 min at
RT. For immunocytochemistry of endogenous -catenin, cells were fixed
and incubated with polyclonal anti--catenin (Santa Cruz Biotechnol-
ogy) followed by anti-rabbit FITC conjugate (1:1000). Coverslips were
coated with 1 mg/ml p-phenylenediamine in 75% glycerol, 0.25 PBS
prior to mounting and visualization. Images were viewed using a Zeiss
Axioskop II microscope.
Luciferase Reporter Assays—NLT cells were grown in 5% charcoal-
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stripped fetal bovine serum in Opti-MEM for 36–48 h prior to trans-
fection. Cells were transfected using LipofectAMINE Plus (Invitrogen)
with 1 g of the luciferase reporter construct (MMTV-LUC or pGL3-
OT), 0.5 g of -catenin, 0.3 g of TCF-4, and 0.5 g of either pCMV-AR
or empty control pCMV vector. Cells were also transfected with 0.1 g
of RSVgal to control for transfection efficiency. Cells were harvested
16–18 h post-transfection and assayed for luciferase and -galactosid-
ase activities as described previously (37).
Statistical Analysis—Comparisons between ethanol control, and 5-
DHT-treated samples were analyzed using unpaired t test using Graph-
Pad InStat version 3.02 for Windows, GraphPad Software, San Diego,
CA.
RESULTS
The Armadillo Repeat of -Catenin Binds AR in the Yeast
Two-hybrid Assay—To identify neuronal protein partners of
AR, a cDNA library was prepared from the GT1-7 GnRH cell
line. This library was used in a yeast two-hybrid screen using
an AR deletion mutant (AR-(371–485)) that contained a trun-
cation of amino acids 371–485 (Fig. 1A). This construct was
designed to possess lower transactivation activity in the yeast
two-hybrid system than the wild-type AR, yet still contain AR
domains essential for potential protein-protein interactions, i.e.
N-C domains and DNA-binding domain. From 4  106 clones
screened in the presence of 5-DHT, one of the positive clones
encoded an open reading frame of 236 amino acids. BLAST
analysis against the NCBI protein sequence data base demon-
strated that this open reading frame consisted of amino acids
187–423 of murine -catenin. This region of -catenin spans
the Armadillo repeat region beginning at repeat 2 and ending
in repeat 7 (Fig. 1A). These Armadillo repeats are also neces-
sary for -catenin binding to cadherins, APC, axin, and TCF
transcription factors (38).
The dependence of ligand for the interaction between AR-
(371–485) and -catenin-(187–423) was confirmed using the
yeast two-hybrid assay. Constructs were co-transformed into
the yeast strain Y187 which allowed for quantitative analysis
of the interaction by measuring -galactosidase reporter activ-
ity (Fig. 1B). No measurable -galactosidase activity was de-
tected in the absence of 5-DHT with the bait plasmid alone or
together with -catenin-(187–423). In the presence of 5-DHT,
-galactosidase activity was detected using AR-(371–485)
alone because of the ability of this construct to transactivate
the -galactosidase reporter gene. -Galactosidase activity was
increased 5-fold, however, when the interaction between AR-
(371–485) and -catenin-(187–423) was assayed in the pres-
ence of 5-DHT, confirming the ligand dependence of this
interaction.
AR Interacts with -Catenin in Mammalian Cells—Because
the yeast two-hybrid assay detected an interaction between an
AR deletion mutant and the Armadillo repeat region of -cate-
nin, COS-7 cells were co-transfected with full-length FLAG
-catenin and myc-AR to determine whether AR could interact
with -catenin in mammalian cells. Protein complexes were
immunoprecipitated with anti-Myc and immunoblotted with
anti-FLAG. Fig. 1C demonstrates that FLAG--catenin was
co-immunoprecipitated with AR in cells transfected with both
constructs but not from cells transfected with FLAG--catenin
and control pCMV-myc vector.
To confirm the presence of -catenin in GnRH neuronal cells,
endogenous -catenin was visualized by immunoblot analysis
and immunocytochemistry. By immunoblot analysis, -catenin
was present in both GT1-7 and NLT cell lines, with slightly
higher expression in NLT cells (Fig. 1D). Immunocytochemical
analysis demonstrated that endogenous -catenin was predom-
inantly localized to cell membranes, consistent with its cy-
toskeletal role. Additionally, low levels of diffuse cytoplasmic
staining was apparent in both cell lines (not shown). These
results confirmed the presence of -catenin in GT1-7 and NLT
GnRH neuronal cell lines and are in agreement with previous
studies (39) that investigated the presence and distribution of
-catenin in GT1–1 cells during neurite outgrowth.
-Catenin Co-localizes to the Nucleus with AR—The mecha-
nism of nuclear translocation of -catenin is not completely
understood. To determine whether liganded AR could facilitate
nuclear translocation of -catenin, initial studies were per-
FIG. 1. Androgen receptor interacts with -catenin. A, the rat
AR construct (AR-(371–485)) used in the yeast two-hybrid screen
contains a deletion of the activation domain 1 spanning amino acids
371–485. Alignment of the -catenin fragment isolated from the yeast
two-hybrid screen with full-length -catenin demonstrated that clone 8
spans Armadillo repeat regions 2–7. B, -galactosidase activity in yeast
Y187 cells transformed with AR-(371–485) and -catenin-(187–423) is
ligand-dependent. Data are expressed as mean  S.E., n  4. C, COS-7
cells were transfected with FLAG--catenin and either pCMV1 (lane 1)
or pCMV-myc-AR (lane 2). Cell lysates were immunoprecipitated (IP)
using anti-Myc antibody. Immunoprecipitated samples and total cell
lysates were immunoblotted with anti-FLAG (M2) to detect -catenin.
D, immunoblot analysis of cell lysates from GT1-7 and NLT cells dem-
onstrate the presence of endogenous -catenin. 20 g of total cell lysates
were analyzed by SDS-PAGE and immunoblot analysis using mono-
clonal -catenin antibodies and visualized by ECL.
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formed using GT1-7 cells that were co-transfected with rat AR
and FLAG--catenin. To discriminate nuclear and cytoplasmic
-catenin from cytoskeletal components, cells were transfected
with FLAG--catenin. Co-localization of AR and FLAG--cate-
nin in the nucleus was observed in the presence of 5-DHT (not
shown); however, GT1-7 cells adhered poorly to the slides re-
quired for immunocytochemical analysis. Therefore, further
experiments were performed in the NLT GnRH neuronal cell
line. In co-transfected cells, AR and FLAG--catenin were dis-
tributed between the cytoplasmic and nuclear fractions in the
absence of 5-DHT. In the presence of 5-DHT, however, both
AR and FLAG--catenin were exclusively nuclear, suggesting
that cytoplasmic -catenin translocated to the nucleus with
liganded AR (Fig. 2A). In the absence of AR, 5-DHT alone had
no effect on -catenin localization (data not shown).
The time course for nuclear translocation of AR in response
to 5-DHT has been shown previously to be rapid, within 30
min (3). In the presence of 5-DHT, AR translocated to the
nucleus in NLT cells within 15–30 min (Fig. 2B). FLAG-
catenin also localized to the nucleus within 15–30 min in the
presence of AR and 5-DHT (Fig. 2B), suggesting that a direct
interaction between AR and -catenin was necessary for
co-localization.
Anti-androgens Do Not Translocate -Catenin to the Nucle-
us—The anti-androgenic compounds casodex and hydroxyflut-
amide have been shown previously to target AR to the nucleus;
however, they do not activate transcription by AR and antag-
onize the physiological effects of androgens (40). To determine
whether these anti-androgens could also induce the co-localiza-
tion of FLAG--catenin with AR, NLT cells were co-transfected
with AR and FLAG--catenin and treated with either 100 nM
casodex or hydroxyflutamide. Although these anti-androgens
induced nuclear localization of AR, they failed to result in
-catenin translocation (Fig. 2C). Flutamide, which binds AR
with very low affinity (40), did not induce nuclear translocation
of AR or FLAG--catenin (data not shown). The fact that caso-
dex and hydroxyflutamide induced nuclear translocation of AR
but not -catenin suggests that translocation of AR alone is not
sufficient to induce complete nuclear localization of -catenin
and that agonist, but not antagonist, -bound AR was required.
Because transfected -catenin is distributed between the
nucleus and cytoplasm in the absence of 5-DHT, an alterna-
tive explanation for the nuclear co-localization of AR with
-catenin might be that 5-DHT treatment induced cytoplas-
mic -catenin degradation, thus leaving only the nuclear frac-
tion. The balance between cytoplasmic and nuclear -catenin
during development and Wnt signaling is due to the regulation
of degradation and stabilization of cytoplasmic -catenin (27).
Cytoplasmic -catenin is rapidly degraded through a proteoso-
mal pathway following phosphorylation by GSK-3 (25, 26). To
exclude the possibility that liganded AR was activating
GSK-3 and thus enhancing the cytoplasmic degradation of
-catenin, immunocytochemical localization experiments were
performed in the presence of 20 mM LiCl, an inhibitor of the
GSK-3 pathway (31). No changes were observed in the pattern
of nuclear co-localization in the absence or presence of LiCl
(data not shown). Furthermore, when NLT cells were trans-
fected with AR and treated with 5-DHT, there was no change
in the activity of GSK-3 as determined by anti-phospho-
GSK-3 immunoblot analysis (Fig. 2D). Because GSK-3 acti-
vation is downstream of the phosphatidylinositol 3-kinase
pathway, we also tested the phosphatidylinositol 3-kinase in-
hibitor wortmannin in the nuclear translocation assay, and it
had no effect (data not shown). These results confirm that the
GSK-3 is not influential in the shuttling of cytoplasmic -cate-
nin to the nucleus.
In addition to the effects of AR as a transcription factor,
liganded AR is known to activate the ERK mitogen-activated
protein kinase pathway through a non-genomic mechanism (4,
FIG. 2. Androgen receptor induces nuclear localization of
-catenin. A, NLT cells were transfected with rat AR and FLAG--
catenin and were either untreated (upper panel) or treated with 10 nM
5-DHT for 18 h (lower panel). Cells were fixed and visualized for AR
using anti-AR (PA1–111A) followed by a Texas Red conjugated second-
ary anti-rabbit antibody. -Catenin was visualized using anti-FLAG
(M2) followed by a FITC-conjugated secondary anti-mouse antibody. B,
NLT cells were transfected with rat AR and FLAG--catenin and
treated with 10 nM 5-DHT for either 15 (upper panel) or 30 min (lower
panel). AR and -catenin were visualized as in A. C, NLT cells were
transfected with rat AR and FLAG--catenin and treated for 18 h with
either 100 nM casodex (upper panel) or 100 nM OH-flutamide (lower
panel). AR and -catenin were visualized as in A. (Magnification,
400.) D, liganded AR does not activate GSK-3. NLT cells were either
untransfected (lanes 1 and 2) or transfected with pCMV-rAR (lanes 3
and 4) and either untreated (lanes 1 and 3) or treated with 10 nM
5-DHT (lanes 2 and 4). Phospho-GSK-3 was determined by SDS-
PAGE and immunoblot analysis using a phospho GSK-3 antibody
(Cell Signaling). Total GSK-3 was determined using GSK-3 antibody
(Transduction Laboratories). Proteins were visualized by ECL.
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5). We tested the ability of the MEK1/2 inhibitor PD98059 on
AR-mediated translocation of -catenin, and this compound
also had no effect on nuclear translocation (data not shown).
Taken together, these data suggest that a direct interaction
between AR and -catenin occurs, and co-nuclear translocation
is responsible for the nuclear accumulation of -catenin in the
presence of 5-DHT.
PR, GR, and ER Do Not Translocate -Catenin to the Nu-
cleus—To determine the specificity of other steroid hormone
receptors for translocation of -catenin, NLT neuronal cells
were co-transfected with FLAG--catenin and either PR, GR,
or ER. PR was both cytoplasmic and nuclear in the absence of
the PR ligand, R5020, but shifted to a completely nuclear
localization in the presence of ligand. FLAG--catenin, how-
ever, remained diffusely distributed in the cell either in the
absence or presence of R5020 (Fig. 3A). Similarly, GR in the
presence of dexamethasone completely translocated to the nu-
cleus, whereas -catenin staining remained cytoplasmic (Fig.
3B). ER localized to the nucleus in the absence or presence of
17-estradiol. However, -catenin failed to co-localize with
ER to the nucleus (Fig. 3C). Together, these results demon-
strate that liganded AR is unique among these steroid recep-
tors in its ability to co-localize -catenin to the cell nucleus in
GnRH neuronal cells.
The Carboxyl Terminus of AR Is Required to Translocate
Cytoplasmic -Catenin to the Nucleus—AR-dependent tran-
scriptional activity is dependent on interactions between the
amino and carboxyl termini of the receptor (30, 41). To test for
androgen receptor domains that mediate nuclear co-localiza-
tion with -catenin, NLT cells were co-transfected with FLAG-
-catenin and several mutant forms of the androgen receptor.
AR-(1–503) is a truncated AR lacking the DNA and ligand
binding domains of the receptor (2). This truncated receptor
lacks the nuclear localization signal of AR and remained cyto-
plasmic in the absence or presence of 5-DHT (Fig. 4A). Ex-
pression of AR-(1–503) failed to induce nuclear translocation of
the -catenin (Fig. 4A). AR-(1–660) is truncated after the DNA
binding domain but prior to the ligand binding domain (2). This
construct is active toward AR-responsive promoters in the ab-
sence or presence of androgen (2). Expression of AR-(1–660)
was constitutively nuclear in neuronal cells in the absence or
presence of 5-DHT. Nuclear -catenin was more prominent in
the AR-(1–660) transfected cells when compared with the full-
length receptor in the absence of 5-DHT (Fig. 2A) but did not
completely translocate -catenin to the nucleus (Fig. 4B) when
compared with the full-length receptor in the presence of 5-
DHT (Fig. 2A).
One mechanism by which anti-androgens are thought to act
is by disruption of N-C interactions of AR and thereby inhibi-
tion of co-activator binding (42). Because anti-androgens in-
duced AR nuclear translocation, but not that of -catenin, we
investigated the co-translocation of -catenin with mutant ARs
that are defective in either N-C interaction or p160 co-activator
binding (32). The results of these experiments are summarized
in Table I. AR K720A, which is functional for N-C interactions
but is defective for co-activator binding, and AR E897K and
V716R, which are defective for N-C interactions, were each
effective in translocating -catenin to the nucleus. Addition-
ally, as would be expected, the yeast two-hybrid bait construct
FIG. 3. -Catenin nuclear translocation is not induced by PR,
GR, or ER. NLT cells were transfected with FLAG--catenin and the
indicated human steroid receptors (SR), either PR (A), GR (B), or ER
(C). Transfected cells were either untreated or treated with 10 nM
R5020 for PR, 100 nM dexamethasone (Dex) for GR, and 50 nM 17-
estradiol for ER for 18 h. Cells were fixed and visualized as described
under “Experimental Procedures.” In each case, the steroid receptors
were visualized using a Texas Red secondary conjugated antibody, and
-catenin was visualized using a FITC secondary conjugated antibody.
(Magnification, 400.)
FIG. 4. -Catenin nuclear translocation is not induced by AR-
(1–503) or AR-(1–660). NLT cells were transfected with FLAG--
catenin and either human AR-(1–503) (A) or AR-(1–660) (B) and either
untreated (DHT) or treated with 10 nM 5-DHT (DHT) for 18 h. The
AR constructs and -catenin were visualized as in Fig. 2. (Magnifica-
tion, 400.)
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AR-(371–485) which interacted with -catenin also induced
-catenin translocation. Taken together, these data suggest
that the carboxyl-terminal hormone binding domain of AR is
required for complete -catenin translocation; however, func-
tional N-C interactions or p160 co-activator binding are not
required.
Nuclear Translocation of AR Is Required for Nuclear Trans-
location of -Catenin—Our results with the deletion mutants
AR-(1–503) and AR-(1–660) suggested that the carboxyl termi-
nus as well as nuclear localization of AR were required to
translocate -catenin to the nucleus. To determine whether
nuclear localization of -catenin was dependent upon nuclear
translocation of AR, -catenin translocation was tested using
the AR construct R617K618,632,633M, which is defective for
nuclear localization in the presence of androgen (31). This
mutated AR contains methionine substitutions for the basic
amino acids at positions 617, 618, 632, and 633 located within
the nuclear localization signal of AR. In GnRH neuronal cells,
AR R617K618,632,633M was defective for nuclear localization
in the absence or presence of 5-DHT and did not translocate
-catenin to the nucleus (Table I). These data demonstrate that
nuclear translocation of agonist-bound AR was required for
-catenin nuclear localization.
Ligand-dependent Repression of AR and -Catenin/TCF-me-
diated Transcription—Korinek et al. (43) have recently demon-
strated the stimulation of a TCF promoter-luciferase reporter
construct in cell lines transfected with -catenin and TCF-4. To
determine whether the interaction between AR and -catenin
could modulate -catenin-dependent transcriptional activity of
a -catenin/TCF-responsive promoter, NLT GnRH neuronal
cells were transfected with AR, TCF-4, and -catenin and the
reporter plasmid pGL3-OT. The luciferase reporter plasmid
pGL3-OT contains a trimerized TCF optimal promoter se-
quence upstream of the luciferase gene (35). In agreement with
previous studies (43), minimal reporter activity was observed
in the absence of transfected TCF-4 and -catenin in GnRH
neuronal cells. This activity was unaffected by AR in the ab-
sence of 5-DHT but was repressed by 27% in the presence of
AR plus 5-DHT (Fig. 5A). Co-expression of TCF-4 and -cate-
nin resulted in a luciferase reporter activity increase of 35-fold.
In the absence of 5-DHT, AR did not modulate this activity.
However, in the presence of 5-DHT, luciferase activity was
blunted to only 8-fold, a repression of 75% (Fig. 5A).
Because ligand-bound AR modulated the transcriptional ac-
tivity of the -catenin-TCF complex, we investigated the ability
of the -catenin-TCF complex to modulate AR transcriptional
activity. NLT cells were transfected with the AR-responsive
reporter construct MMTV-LUC and either AR alone or in com-
bination with -catenin/TCF-4 (Fig. 5B). In the presence of
5-DHT, AR stimulated MMTV-luciferase activity 18-fold. In
the absence of AR, -catenin/TCF-4 had a modest 2-fold stim-
ulatory activity on MMTV-luciferase in the absence or presence
of 5-DHT. However, in the presence of 5-DHT and AR,
-catenin/TCF-4 repressed AR stimulation of MMTV-luciferase
to only 7-fold, a 61% repression. Together, these data suggest a
functional interaction between liganded AR and -catenin/TCF
that effectively represses both AR and -catenin/TCF-mediated
activation of gene transcription in neuronal cells.
DISCUSSION
Transcriptional activity of steroid hormone receptors re-
quires accessory proteins to act as either co-activators or co-
repressors. We used a yeast two-hybrid screen to identify AR-
binding proteins in a neuronal cell cDNA library. We identified
-catenin as a novel AR-interacting protein. Furthermore, li-
ganded AR enhanced the nuclear translocation of -catenin
and modulated -catenin/TCF-dependent transcriptional
activity.
The mechanisms of nuclear translocation of -catenin are not
completely understood. Cytoplasmic levels of -catenin are
tightly regulated by GSK-3-dependent phosphorylation and
TABLE I
Steroid receptor and -catenin nuclear co-localization
Steroid receptor constructs were co-transfected into NLT GnRH neu-
ronal cells with FLAG--catenin. Intracellular localization of the ste-
roid receptors and FLAG--catenin was determined by immunocyto-
chemistry as described under “Experimental Procedures.” The
respective single amino acid mutations of the human AR are indicated
for AR K720A, E897K, and V716R; R617K618,632,633M contains four
methionine substitutions at the indicated basic amino acids; AR-(1–
503) and AR-(1–660) are AR truncation deletion mutants of the human
AR; PR, GR, and ER are human progesterone, glucocorticoid, and
estrogen receptor , respectively.  indicates complete nuclear trans-
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AR E897K  
AR V716R  







FIG. 5. AR and -catenin/TCF-mediated transcriptional activ-
ity are suppressed in GnRH neuronal cells. NLT cells were trans-
fected with rat AR, -catenin, and TCF-4 and assayed for either -cate-
nin/TCF-4 transcriptional activity using a TCF/Lef-luciferase (pGL3-
OT) reporter construct (A), or AR transcriptional activity using MMTV-
luciferase as a reporter system (B). Cells were either untreated (EtOH
vehicle control) or treated with 10 nM 5-DHT. Data are expressed as
mean  S.E. from three independent experiments as relative activity
normalized to pCMV1. *, p 	 0.05 compared with EtOH vehicle control.
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subsequent proteosomal degradation. Accumulation of cyto-
plasmic -catenin through either activation of Wnt signaling or
conversely in cancers expressing mutated and degradation-
resistant -catenin results in nuclear translocation. Proteins
larger than 40 kDa are generally excluded from the nucleus
unless they contain a nuclear localization signal (NLS) (re-
viewed in Ref. 44). Because -catenin is 95 kDa, it is unlikely
to enter the nucleus in a passive manner. However, -catenin
does not contain a nuclear localization signal, and its import
into the nucleus is independent of the importin/karyopherin
and Ran pathways (45, 46). Previous studies (47–49) have
shown that co-expression of TCF proteins enhanced -catenin
nuclear localization. Additionally, the adenomatous polyposis
coli tumor suppressor protein can shuttle -catenin to the
nucleus (50). Together, these results suggest that accessory
proteins are required to chaperone -catenin into the nucleus.
In addition to these proteins, our results demonstrated that
agonist bound AR but not GR, PR, or ER translocated -cate-
nin to the nucleus, supporting the hypothesis that in androgen
target tissues liganded AR may be a nuclear shuttling protein
for -catenin.
The mechanism by which AR translocates -catenin to the
nucleus appears to be due to the direct protein-protein inter-
action and not through secondary signaling events. AR did
not activate GSK-3 activity in neuronal cells; therefore, the
accumulation of nuclear -catenin could not be attributed to
a loss of cytoplasmic -catenin. The time course for the nu-
clear translocation of -catenin also paralleled that of AR.
However, although AR was completely nuclear and the ma-
jority of -catenin was nuclear after 15–30 min, some cyto-
plasmic staining of -catenin was still observed. After 18 h
however, complete AR and -catenin nuclear localization was
seen. The residual cytoplasmic -catenin seen 15–30 min
after treatment with 5-DHT may be due to a pool of -cate-
nin that was not in direct proximity with AR. Because we
have observed nuclear -catenin in transfected cells in the
absence of AR and 5-DHT, some -catenin enters the cell
nucleus in the absence of AR. It is possible that following
treatment with 5-DHT in AR-transfected cells, residual cy-
toplasmic -catenin could subsequently enter the nucleus in
an AR-independent manner. Once in the nucleus, this pool of
-catenin could be sequestered by agonist-bound AR, thus
demonstrating complete nuclear localization of -catenin. Be-
cause the majority of -catenin enters the cell nucleus with
the same kinetics as AR, these results support a role for
direct protein-protein interactions between AR and -catenin
in the process of nuclear co-localization.
To investigate whether functional AR was required for the
translocation of -catenin, AR mutants were tested for their
ability to translocate -catenin. By using the truncated AR-
(1–503) and the nuclear translocation-deficient mutant
R617K618,632,633M, neither the mutated receptors nor
-catenin was translocated to the nucleus. The truncation mu-
tant AR-(1–660) was constitutively nuclear in the absence or
presence of ligand, yet failed to completely translocate -cate-
nin like the full-length receptor. However, enhanced nuclear
localization of -catenin was observed with AR-(1–660) when
compared with full-length AR in the absence of 5-DHT or
-catenin alone, suggesting that AR-(1–660) could interact
with -catenin. The mechanism for the inability of AR-(1–660)
to completely translocate -catenin to the nucleus is not clear.
It is possible that the AR carboxyl terminus, containing the
hormone binding domain, participates in the interaction with
-catenin. Alternatively, without the hormone binding domain,
AR-(1–660) is constitutively nuclear and does not occupy the
same cytoplasmic compartment with -catenin and therefore
cannot interact with most of the cytoplasmic -catenin. Al-
though AR-(1–660) may enhance the translocation of -catenin
to the nucleus, these data demonstrate that the carboxyl ter-
minus of AR is required for complete -catenin nuclear
co-translocation.
Because the carboxyl terminus of AR interacts with the
amino terminus to recruit p160 family of co-activators for AR-
mediated transcription, our results with wild-type, AR-(371–
485), and AR-(1–660) suggested that functional N-C interac-
tions and ability of AR to recruit co-activators might be
required for AR and -catenin co-translocation. To test this
hypothesis, we used the mutant AR constructs K720A, E897K,
and V716R which are deficient for recruitment of p160 co-
activators. Additionally, AR V716R and E897K do not form
functional N-C interactions (32). However, all of these con-
structs effectively co-translocated -catenin to the nucleus (Ta-
ble I), demonstrating that neither functional N-C interactions
nor p160 co-activator binding were essential for -catenin co-
translocation. However, our results with the AR antagonists
suggest that nuclear translocation alone of full-length AR is not
sufficient to translocate -catenin to the nucleus. In several
laboratories, casodex and hydroxyflutamide have previously
been shown to translocate AR to the nucleus, but did not induce
DNA binding (24, 30). In neuronal cells, these anti-androgens
induced nuclear localization of AR but not -catenin. Together,
our results suggest that for complete nuclear translocation of
-catenin the carboxyl terminus of AR is important and that
liganded AR must be in a correct conformation to allow DNA
binding. However, N-C interactions and p160 co-activator re-
cruitment do not appear to be essential.
The role of -catenin/TCF signaling in normal physiology of
cells is not well understood. Downstream target genes of the
-catenin/TCF pathway include Myc, Fra, and Jun (35, 51),
cyclin D-1 (52) and matrix metalloproteinase-7 (53). These
genes are involved in normal growth and development as well
in tumorigenesis. Mutated forms of -catenin have been iden-
tified in tumors including colon, prostate, ovaries, and thyroid
(54–60). Transforming mutations in -catenin are concen-
trated at the amino terminus, which contains consensus phos-
phorylation sites for GSK-3. These mutations inhibit the
phosphorylation of -catenin and its subsequent degradation,
thereby increasing both the cytoplasmic and nuclear fractions
of cellular -catenin (reviewed in Ref. 61). Unregulated nuclear
accumulation of -catenin leads to a transformed phenotype
through up-regulation of -catenin/TCF-responsive genes. The
interaction of AR with -catenin suggests that AR may play a
role in either the physiologic or pathophysiologic functions of
-catenin/TCF.
Our findings suggest that AR attenuates transcriptional
activity of the -catenin-TCF complex in GnRH neuronal
cells. Endogenous -catenin and TCF activity are present in
GnRH neuronal cells; however, in the absence of co-
transfected -catenin and TCF-4, low TCF-luciferase re-
porter activity was observed. This activity was decreased by
27% by agonist-bound AR, demonstrating that AR repressed
endogenous -catenin/TCF signaling. Consistent with the re-
sults of Korinek et al. (43), in which activation of TCF-
luciferase reporter in the B-cell line IIA1.6 required co-
transfection with -catenin and TCF-4, co-transfection of
-catenin and TCF-4 was required to maximally stimulate
TCF-luciferase reporter activity in GnRH neuronal cells. The
low level of activation of TCF-luciferase reporter activity in
untransfected cells may be due to low expression of endoge-
nous TCF proteins or to the localization of endogenous -cate-
nin. In the absence of mutated -catenin or Wnt signaling,
-catenin is primarily extra-nuclear, and therefore low tran-
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scriptional activity of the -catenin/TCF pathway is ob-
served. When transfected with a -catenin expression plas-
mid, the distribution of -catenin is both cytoplasmic and
nuclear. Because overexpressed -catenin is partially nu-
clear, this effect may mimic the nuclear localization observed
during Wnt signaling or by degradation-resistant forms of
mutated -catenin. These results raise the possibility that
agonist-bound AR may modulate aberrant -catenin/TCF sig-
naling in tumors of androgen-dependent tissues that contain
mutated forms of -catenin. For example, Truica et al. (62)
recently showed that AR could interact with both wild-type
and a phosphorylation-defective S33F -catenin mutant in
the LnCAP prostate cancer cell line. In contrast to our studies
in which cells were co-transfected with AR, -catenin, and
TCF-4, the LnCAP experiments involved transfection with
-catenin alone. In our studies, -catenin/TCF attenuated
AR-stimulated MMTV-luciferase activity, whereas in LnCAP
cells -catenin enhanced AR target gene reporter activity up
to 4-fold and enhanced the sensitivity of AR to weak AR
agonists including androstenedione, dehydroepiandros-
terone, and 17-estradiol. Together with these results, our
data suggest that the functional consequences of the interac-
tion of AR with -catenin may also be dependent upon the
levels of nuclear TCF proteins.
In addition to interactions between AR and -catenin,
other nuclear receptor pathways have recently been shown to
modulate -catenin/TCF-mediated transcription. The reti-
noic acid receptor can also interact with -catenin and cross-
talks with the -catenin/TCF pathway (63). In those studies,
9-cis-retinoic acid inhibited -catenin/TCF reporter signaling
in several tumor cell lines, and mutated -catenin augmented
retinoic acid receptor-mediated gene expression in MCF-7
cells. In addition, estrogen receptors were also shown to
modulate -catenin/TCF reporter gene activity (64). Rather
than interacting with -catenin, these studies demonstrated
that the interaction between ER occurred with TCF family
members. Curiously, TCF-4 antagonized but TCF-1 stimu-
lated the transcriptional activity of ER. These data support
cross-talk of -catenin and liganded steroid receptors that
may be cell type- or promoter-specific and may be dependent
upon the complement of TCF transcription factors present in
the cells.
In summary, we have identified -catenin as a liganded
AR-interacting protein in neuronal cells. In addition, agonist
but not antagonist-bound AR shuttles -catenin to the nucleus,
and this effect was specific to AR but not PR, GR, or ER.
Within the nucleus, AR and -catenin/TCF antagonize each
other’s effects on promoter activity in neuronal cells. Together
these experiments and other emerging data suggest that ste-
roid receptors may cross-talk with the -catenin/TCF at several
levels and may modulate the actions of the -catenin/TCF
pathway in normal development as well as pathophysiologic
conditions.
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